breastscreeningai.github.io/platform.html at main · BreastScreeningAI/breastscreeningai.github.io · GitHub

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
<!DOCTYPE html>
<html class="no-js" lang="en">
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="x-ua-compatible" content="ie=edge" />
    <title>Platform | BreastScreening-AI</title>
    <meta name="description" content="Explore BreastScreening-AI's multimodal platform, operational value, evidence-backed performance and modeled market impact." />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <meta property="og:title" content="Platform | BreastScreening-AI" />
    <meta property="og:description" content="A multimodal breast imaging platform designed to increase specialist capacity, support quality and create measurable operational value." />
    <meta property="og:url" content="https://breastscreeningai.github.io/platform.html" />
    <meta property="og:type" content="website" />
    <link rel="shortcut icon" type="image/x-icon" href="assets/images/favicon.svg" />
    <link rel="stylesheet" href="assets/css/bootstrap.min.css" />
    <link rel="stylesheet" href="assets/css/icons.css" />
    <link rel="stylesheet" href="assets/css/main.css" />
    <link rel="stylesheet" href="assets/css/evidence.css" />
    <link rel="stylesheet" href="assets/css/solutions.css" />
  </head>
  <body class="solution-page">
    <div class="preloader" aria-hidden="true"><div class="preloader-inner"><div class="preloader-icon"><span></span><span></span></div></div></div>
    <header class="header navbar-area">
      <div class="container"><div class="row align-items-center"><div class="col-lg-12"><div class="nav-inner">
        <nav class="navbar navbar-expand-lg">
          <a class="navbar-brand" href="index.html"><img src="assets/images/logo/logo-bs-main.svg" alt="BreastScreening-AI" /></a>
          <button class="navbar-toggler mobile-menu-btn" type="button" data-bs-toggle="collapse" data-bs-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation"><span class="toggler-icon"></span><span class="toggler-icon"></span><span class="toggler-icon"></span></button>
          <div class="collapse navbar-collapse sub-menu-bar" id="navbarSupportedContent"><ul id="nav" class="navbar-nav ms-auto">
            <li class="nav-item"><a href="#value">Value</a></li>
            <li class="nav-item"><a href="#multimodality">Multimodality</a></li>
            <li class="nav-item"><a href="#impact">Impact</a></li>
            <li class="nav-item"><a href="#adoption">Adoption</a></li>
          </ul></div>
          <div class="button add-list-button"><a href="index.html" class="btn"><i class="lni lni-arrow-left"></i> Main Site</a></div>
        </nav>
      </div></div></div></div>
    </header>

    <main>
      <section class="solution-hero" aria-labelledby="platform-title"><div class="container">
        <p class="solution-kicker">Platform</p>
        <h1 id="platform-title">Turn breast imaging complexity into scalable clinical capacity</h1>
        <p class="solution-lead">BreastScreening-AI is building a clinician-controlled platform for mammography, ultrasound and MRI. It brings image review, AI assistance, explainable interaction and workflow measurement into one product strategy so providers can pursue more capacity, more consistent decisions and a measurable return on responsible AI adoption.</p>
        <div class="solution-tags" aria-label="Platform characteristics"><span>Operational capacity</span><span>Multimodal intelligence</span><span>Quality support</span><span>Measurable adoption</span></div>
      </div></section>

      <nav class="solution-subnav" aria-label="Platform sections"><div class="container"><a href="#value">Business value</a><a href="#capabilities">Platform</a><a href="#multimodality">Multimodality</a><a href="#proof">Proof points</a><a href="#impact">Market impact</a><a href="#adoption">Adoption</a></div></nav>

      <section id="value" class="solution-section white"><div class="container">
        <div class="solution-heading"><p class="solution-label">Business value</p><h2>Stronger Breast Imaging Service</h2><p>The platform is designed around the outcomes that matter to provider executives, clinical leaders and imaging teams: capacity, quality, standardization, adoption, visibility and scalable integration.</p></div>
        <div class="solution-grid">
          <article class="solution-card"><i class="lni lni-timer"></i><h3>Release specialist capacity</h3><p>Reduce avoidable review and interaction time so scarce breast-imaging expertise can be directed toward complex cases, consultation and patient care.</p></article>
          <article class="solution-card"><i class="lni lni-checkmark-circle"></i><h3>Strengthen quality control</h3><p>Add a structured second-reader layer that surfaces potential disagreement while keeping the radiologist responsible for the final assessment.</p></article>
          <article class="solution-card"><i class="lni lni-network"></i><h3>Connect the imaging pathway</h3><p>Create a common product layer across MG, US and MRI rather than purchasing isolated AI experiences for each point in the pathway.</p></article>
          <article class="solution-card"><i class="lni lni-users"></i><h3>Accelerate team adoption</h3><p>Adapt explanations and interaction to different experience levels, supporting a more practical rollout across mixed-seniority clinical teams.</p></article>
          <article class="solution-card"><i class="lni lni-stats-up"></i><h3>Make value measurable</h3><p>Track time, decisions, disagreement, usability and trust alongside model performance to build a customer-specific operational and economic case.</p></article>
          <article class="solution-card"><i class="lni lni-layers"></i><h3>Scale with governance</h3><p>Introduce capabilities through controlled validation gates, with traceability, clinician override and evidence requirements built into deployment planning.</p></article>
        </div>
      </div></section>

      <section id="capabilities" class="solution-section dark"><div class="container">
        <div class="solution-heading"><p class="solution-label">Product platform</p><h2>Assisted Breast Imaging</h2><p>The product direction combines six capabilities that can be purchased, validated and introduced progressively according to customer priorities and the authorized intended use.</p></div>
        <div class="principle-grid">
          <article><h3>Multimodal workspace</h3><p>A coordinated experience for mammography, ultrasound, MRI and relevant case information, while tracking evidence maturity separately for every modality.</p></article>
          <article><h3>AI second reading</h3><p>Classification and lesion-localization outputs provide an additional perspective while preserving clinician review and override.</p></article>
          <article><h3>Explainable assistance</h3><p>Visible findings, contextual arguments and communication adapted to clinician experience support informed rather than automatic reliance.</p></article>
          <article><h3>Workflow measurement</h3><p>Decision changes, time, usability, workload and interaction can be evaluated alongside model performance.</p></article>
          <article><h3>Traceable decisions</h3><p>The intended workflow distinguishes the initial clinician assessment, AI recommendation and final clinician decision.</p></article>
          <article><h3>Progressive integration</h3><p>Technical integration, human factors, clinical validation and economic evaluation are treated as separate deployment gates.</p></article>
        </div>
      </div></section>

      <section id="multimodality" class="solution-section white"><div class="container">
        <div class="solution-heading"><p class="solution-label">Why multimodality</p><h2>Pathway</h2><p>No modality answers every clinical question. A commercially useful platform must support how providers move from population screening to targeted characterization, risk-based assessment, staging and treatment planning. The detailed operational sequence will be developed further in the <a href="workflow.html">Workflow</a> page.</p></div>
        <div class="solution-grid modality-grid">
          <article class="solution-card"><span class="modality-code">MG</span><h3>Mammography: the screening foundation</h3><p>Low-dose mammography is the established population-screening entry point and can reveal early changes, including calcifications. Its scale makes reading efficiency and consistent assessment commercially important, but dense tissue can obscure findings.</p></article>
          <article class="solution-card"><span class="modality-code">US</span><h3>Ultrasound: targeted characterization</h3><p>Ultrasound helps characterize a palpable or imaging-detected abnormality as solid, fluid-filled or mixed, adds real-time soft-tissue information and can guide biopsy. It complements rather than replaces mammography.</p></article>
          <article class="solution-card"><span class="modality-code">MRI</span><h3>MRI: high-sensitivity problem solving</h3><p>MRI provides detailed contrast-enhanced assessment for selected high-risk screening, disease-extent evaluation and further investigation of abnormalities. It adds information that may not be visible on MG or US, with higher cost and access constraints.</p></article>
        </div>
        <p class="source-note">Clinical context: <a href="https://www.who.int/news-room/fact-sheets/detail/breast-cancer" target="_blank" rel="noopener noreferrer">WHO</a>, <a href="https://www.radiologyinfo.org/en/info/mammo" target="_blank" rel="noopener noreferrer">mammography</a>, <a href="https://www.radiologyinfo.org/en/info/breastus" target="_blank" rel="noopener noreferrer">ultrasound</a> and <a href="https://www.radiologyinfo.org/en/info/breastmr" target="_blank" rel="noopener noreferrer">MRI</a>.     Modality selection remains specific to patient characteristics, risk factors, and clinical indication.</p>
      </div></section>

      <section id="proof" class="solution-section soft-blue"><div class="container">
        <div class="solution-heading"><p class="solution-label">Evidence-backed traction</p><h2>Operational and Quality Value</h2><p>Controlled studies provide a quantitative foundation for customer validation. These figures are study outcomes, not guaranteed customer results or routine-care performance claims.</p></div>
        <div class="metric-grid">
          <article class="metric-card"><span class="metric-value">45</span><h3>Clinicians across nine institutions</h3><p>A peer-reviewed comparison of clinician-only and clinician-AI scenarios provides the platform's principal human-AI evidence base.</p><a href="https://doi.org/10.1016/j.artmed.2022.102285" target="_blank" rel="noopener noreferrer">Read the study <i class="lni lni-arrow-top-right"></i></a></article>
          <article class="metric-card"><span class="metric-value">91%</span><h3>Positive clinician response</h3><p>Clinicians reported positive expectations and perceptive satisfaction, supporting the platform's adoption proposition.</p><a href="https://doi.org/10.1016/j.artmed.2022.102285" target="_blank" rel="noopener noreferrer">Read the study <i class="lni lni-arrow-top-right"></i></a></article>
          <article class="metric-card"><span class="metric-value">18.3%</span><h3>Lower mean task time</h3><p>Published means decreased by 69 seconds, from 377 to 308 seconds per experimental case, indicating a potential capacity lever.</p><a href="https://doi.org/10.1016/j.artmed.2022.102285" target="_blank" rel="noopener noreferrer">Inspect the publication <i class="lni lni-arrow-top-right"></i></a></article>
          <article class="metric-card"><span class="metric-value">27% less FPs</span><h3>Lower false-positive proportion</h3><p>False-positive classifications decreased from 54% to 27% in the controlled study.</p><a href="voucher.html#clinical-results">Review the evidence context <i class="lni lni-arrow-right"></i></a></article>
          <article class="metric-card"><span class="metric-value">4% less FNs</span><h3>Lower false-negative proportion</h3><p>False-negative classifications decreased from 6% to 2% under the experimental clinician-AI condition.</p><a href="voucher.html#clinical-results">Review the evidence context <i class="lni lni-arrow-right"></i></a></article>
          <article class="metric-card"><span class="metric-value">25.3%</span><h3>Faster personalized interaction</h3><p>Mean task time decreased from 166.12 to 124.02 seconds with assertiveness-based communication; p = 0.005 and reported r = 0.49.</p><a href="https://doi.org/10.1145/3544548.3580682" target="_blank" rel="noopener noreferrer">Read the CHI study <i class="lni lni-arrow-top-right"></i></a></article>
        </div>
        <p class="metric-note"><strong>Commercial interpretation:</strong> the results support further evaluation of productivity, quality and adoption value. They do not yet establish customer ROI, fewer biopsies, improved cancer detection or realized cost savings.</p>
      </div></section>

      <section id="impact" class="solution-section dark"><div class="container">
        <div class="solution-heading"><p class="solution-label">Modeled market impact</p><h2>What a 69-second capacity gain could mean at scale</h2><p>The scenarios below apply the published experimental mean-time difference to annual review volumes. They illustrate the scale of addressable operational value; they are not a total-addressable-market estimate, forecast, price recommendation or claim of realized savings.</p></div>
        <div class="metric-grid impact-grid">
          <article class="metric-card"><span class="metric-value">19,167 hours</span><h3>Per 1 million annual reviews</h3><p>A 69-second reduction applied to one million reviews equals approximately 12 full-time-equivalent years of capacity, assuming 1,600 productive hours per FTE.</p></article>
          <article class="metric-card"><span class="metric-value">191,667 hours</span><h3>At 10 million annual reviews</h3><p>The same scenario equals approximately 120 FTE-years of potential capacity across a large screening system or multi-market provider network.</p></article>
          <article class="metric-card"><span class="metric-value">€14.4m–€28.8m</span><h3>Illustrative annual capacity value</h3><p>At 10 million reviews and an assumed fully loaded specialist-hour value of €75–€150, released capacity would have this modeled gross value before implementation costs.</p></article>
          <article class="metric-card"><span class="metric-value">958,333 hours</span><h3>At 50 million annual reviews</h3><p>A broader cross-system scenario equals approximately 599 FTE-years of potential capacity. Actual eligible volumes and workflow effects would require country-level validation.</p></article>
          <article class="metric-card"><span class="metric-value">€71.9m–€143.8m</span><h3>Broader-system capacity value</h3><p>This applies the same €75–€150 hourly assumption to 50 million reviews. It represents capacity value, not cash savings, revenue or net economic benefit.</p></article>
          <article class="metric-card"><span class="metric-value">2.3 million</span><h3>Global diagnoses in 2022</h3><p>WHO estimates 2.3 million women were diagnosed and 670,000 died from breast cancer in 2022, underscoring the global need for timely, scalable breast-care pathways.</p><a href="https://www.who.int/news-room/fact-sheets/detail/breast-cancer" target="_blank" rel="noopener noreferrer">Review WHO context <i class="lni lni-arrow-top-right"></i></a></article>
        </div>
        <div class="impact-method"><h3>Transparent model</h3><p><strong>Capacity hours</strong> = annual reviews × 69 seconds ÷ 3,600. <strong>FTE-years</strong> = capacity hours ÷ 1,600. <strong>Gross capacity value</strong> = capacity hours × assumed €75–€150 per specialist hour.</p><p>The model excludes software, integration, infrastructure, training, governance and change-management costs. It also excludes downstream benefits from fewer false positives or false negatives because the controlled study proportions cannot yet be translated responsibly into avoided recalls, biopsies, delayed diagnoses or treatment costs.</p></div>
      </div></section>

      <section id="customers" class="solution-section white"><div class="container">
        <div class="solution-heading"><p class="solution-label">Go-to-market fit</p><h2>Value Proposition</h2><p>The platform is relevant where breast imaging quality, specialist capacity, multimodal coordination and responsible AI adoption are strategic priorities.</p></div>
        <div class="evidence-comparison">
          <article><span class="evidence-year">Providers</span><h3>Hospitals and imaging centers</h3><p>Potential value lies in workflow capacity, second-reading support, quality measurement and a structured route for evaluating AI before wider adoption.</p></article>
          <article><span class="evidence-year">Networks</span><h3>Multi-site healthcare groups</h3><p>A common platform can support standardized evaluation, cross-site performance monitoring and consistent governance across different teams.</p></article>
          <article><span class="evidence-year">Technology</span><h3>PACS and imaging partners</h3><p>The multimodal and explainable-interaction strategy offers a differentiated application layer for approved imaging ecosystems and integration programs.</p></article>
          <article><span class="evidence-year">Innovation</span><h3>Clinical research programs</h3><p>The platform can support prospective validation, reader studies, human-factors testing and health-economic evidence generation.</p></article>
        </div>
      </div></section>

      <section id="adoption" class="solution-section soft-green"><div class="container">
        <div class="solution-heading"><p class="solution-label">Adoption path</p><h2>Convert product evidence into customer value</h2><p>Healthcare customers need more than an algorithm. Adoption depends on integration, clinical validation, governance, training and a value case grounded in local workflow and cost data.</p></div>
        <div class="boundary-grid">
          <article class="boundary-card"><h3>Current assets</h3><ul><li>Peer-reviewed clinician studies with cohorts of 31, 45 and 52 participants.</li><li>Research across mammography, ultrasound and MRI.</li><li>Protected multimodal and clinician-adaptive intellectual property.</li><li>Project-level TRL 5 progressing toward TRL 6.</li></ul></article>
          <article class="boundary-card caution"><h3>Required before scaled adoption</h3><ul><li>Locked intended use and product configuration.</li><li>Independent multicenter and prospective clinical validation.</li><li>Quality management, regulatory authorization and post-market controls.</li><li>Customer-specific budget impact and return-on-investment evidence.</li></ul></article>
        </div>
        <div class="status-panel platform-status"><div><h3>Commercial position</h3><p>BreastScreening-AI remains research software under progressive product, human-factors and clinical evaluation. Commercial discussions should focus on validation partnerships, integration planning and evidence generation rather than claims of current clinical authorization.</p><a href="mailto:info@breastscreeningai.com" class="doi-link">Discuss a validation partnership <i class="lni lni-arrow-right"></i></a></div><div class="status-fact"><strong>Human first</strong><span>Product principle</span><p>The platform is designed to strengthen clinical judgement. A qualified clinician retains responsibility for interpretation and patient management.</p></div></div>
      </div></section>

      <section class="solution-cta"><div class="container"><h2>Evaluate the platform in your clinical environment</h2><p>Explore the intended workflow or contact the team about validation, integration and evidence partnerships.</p><a href="workflow.html" class="btn">Explore workflow</a> <a href="mailto:info@breastscreeningai.com" class="btn btn-outline-light business-cta-secondary">Contact the team</a></div></section>
    </main>

    <footer class="secondary-footer"><div class="container"><div class="secondary-footer-grid"><div class="secondary-footer-brand"><a href="index.html"><img src="assets/images/logo/logo-bs-ai-2.svg" alt="BreastScreening-AI" /></a><p>AI should strengthen, not replace, clinical judgement.</p><ul class="secondary-footer-social"><li><a href="https://www.linkedin.com/company/breastscreeningai" target="_blank" rel="noopener noreferrer" aria-label="BreastScreening-AI on LinkedIn"><i class="lni lni-linkedin-original"></i></a></li><li><a href="https://breastscreeningai.substack.com/feed" target="_blank" rel="noopener noreferrer" aria-label="BreastScreening-AI RSS feed"><i class="lni lni-rss-feed"></i></a></li></ul></div><nav class="secondary-footer-nav" aria-label="Business"><h2>Business</h2><ul><li><a href="platform.html">Platform</a></li><li><a href="workflow.html">Workflow</a></li><li><a href="https://www.crunchbase.com/organization/breastscreening-ai" target="_blank" rel="noopener noreferrer">Analytics</a></li><li><a href="https://www.f6s.com/breastscreeningai" target="_blank" rel="noopener noreferrer">Insights</a></li></ul></nav><nav class="secondary-footer-nav" aria-label="Support"><h2>Support</h2><ul><li><a href="https://github.com/BreastScreeningAI/meta/wiki" target="_blank" rel="noopener noreferrer">Documentation</a></li><li><a href="index.html#live-support">Live</a></li><li><a href="mailto:info@breastscreeningai.com">Contact</a></li><li><a href="faq.html">FAQs</a></li></ul></nav><nav class="secondary-footer-nav" aria-label="Company"><h2>Company</h2><ul><li><a href="https://github.com/BreastScreeningAI/meta" target="_blank" rel="noopener noreferrer">About</a></li><li><a href="story.html">Story</a></li><li><a href="https://wellfound.com/company/breastscreening-ai/jobs" target="_blank" rel="noopener noreferrer">Careers</a></li><li><a href="reports.html">Reports</a></li></ul></nav><nav class="secondary-footer-nav" aria-label="Legal"><h2>Legal</h2><ul><li><a href="media/legal/breastscreeningai_terms_and_conditions.pdf" target="_blank" rel="noopener noreferrer">Terms</a></li><li><a href="media/legal/breastscreeningai_privacy_policy.pdf" target="_blank" rel="noopener noreferrer">Privacy</a></li><li><a href="media/legal/breastscreeningai_cookie_policy.pdf" target="_blank" rel="noopener noreferrer">Cookies</a></li><li><a href="media/legal/breastscreeningai_disclaimer.pdf" target="_blank" rel="noopener noreferrer">Disclaimer</a></li></ul></nav><nav class="secondary-footer-nav" aria-label="Explore"><h2>Explore</h2><ul><li><a href="evidence.html">Evidence</a></li><li><a href="publications.html">Publications</a></li><li><a href="news.html">News</a></li><li><a href="media.html">Media</a></li></ul></nav></div><div class="secondary-footer-support"><div class="secondary-footer-funding"><a href="https://recuperarportugal.gov.pt/" target="_blank" rel="noopener noreferrer"><img src="assets/recognitions/startup_voucher_2025.png" alt="Startup Voucher 2025" /></a><a href="https://www.fct.pt/" target="_blank" rel="noopener noreferrer"><img src="assets/recognitions/2022_FCT_Logo_A_horizontal_branco_cropped.png" alt="Fundacao para a Ciencia e a Tecnologia" /></a></div><p class="secondary-footer-disclaimer">Research software and information only. BreastScreening-AI does not provide medical advice, diagnosis, or emergency services.</p></div></div></footer>
    <a href="#" class="scroll-top" aria-label="Back to top"><i class="lni lni-chevron-up"></i></a>
    <script src="assets/js/bootstrap.min.js"></script><script src="assets/js/wow.min.js"></script><script src="assets/js/main.js"></script>
  </body>
</html>